Foregrounds and Prospects of Anti-Tumor Immunotherapy Based on Oncolytic Adenovirus

Abstract: The immune system has great potential in the anti-tumor process， but the immunosuppressive state of tumor microenvironment (TME) can trigger a series of tumor immune escape reactions， which makes the cancer be further deteriorated. Oncolytic adenovirus (OAds) can kill tumor cells through selective replication and oncolytic effect， which can expose tumor-associated antigens， activate immune cells and reverse TME， eventually trigger a series of anti-tumor immunoreaction. However， OAds has defects of low target and high immunogenicity， which led to its low immunotherapy effect. Thus， it is necessary to modify OAds to improve its tumor targeting and reduce its immunogenicity. Moreover， immunotherapy gene-armed OAds will improve its anti-cancer activity significantly. This paper reviews the progress of the mechanism of tumor immunotherapy and anti-tumor immunotherapy of OAds.

CSTR: 32200.14.cjcb.2018.06.0021